摘要
YAP1和转录共激活因子与PDZ结合基序与许多转录因子一起调控基因转录。YAP1和TAZ由肿瘤抑制性的Hippo病理通路负面地调控,在人类肿瘤中,Hippo通路经常失去控制并且YAP1和TAZ能躲避Hippo通路的抑制,YAP1和TAZ的上调诱导了上皮细胞间质转化与肿瘤细胞耐药性增加。TAZ与肿瘤干细胞有关,结果是与高度表达的YAP1和TAZ肿瘤与临床预后有关。YAP1和TAZ的抑制剂被认为在肿瘤治疗中是有益的。另一方面,因为YAP1和TAZ在各种组织干细胞和组织修复的调节中起着非常重要的角色,YAP1和TAZ的激活物在再生医学中很有用。本文讨论了YAP1和TAZ的抑制剂和激活剂在人类疾病中潜在的应用和综述了检索这些制剂的药物筛选的过程。
关键词: 肿瘤,药物筛选,再生,肌肉减少症,肿瘤抑制剂
Current Drug Targets
Title:The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine
Volume: 18 Issue: 4
关键词: 肿瘤,药物筛选,再生,肌肉减少症,肿瘤抑制剂
摘要: Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding motif (TAZ) co-operate with numerous transcription factors to regulate gene transcriptions. YAP1 and TAZ are negatively regulated by the tumor suppressive Hippo pathway. In human cancers, the Hippo pathway is frequently deregulated and YAP1 and TAZ escape the inhibition by the Hippo pathway. The upregulation of YAP1 and TAZ induces epithelial-mesenchymal transition and increases drug resistance in cancer cells. TAZ is implicated in cancer stemness. In consequence cancers with hyperactive YAP1 and TAZ are associated with poor clinical prognosis. Inhibitors of YAP1 and TAZ are reasoned to be beneficial in cancer therapy. On the other hand, since YAP1 and TAZ play important roles in the regulation of various tissue stem cells and in tissue repair, activators of YAP1 and TAZ are useful in the regenerative medicine. We discuss the potential application of inhibitors and activators of YAP1 and TAZ in human diseases and review the progress of drug screenings to search for them.
Export Options
About this article
Cite this article as:
The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160112115641
DOI https://dx.doi.org/10.2174/1389450117666160112115641 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Proposed Biomarkers of Anthracycline Cardiotoxicity in Cancer: Emerging Opportunities in Oxidative Damage and Autophagy
Current Molecular Medicine ERRATUM
Current Cancer Drug Targets Recent Development in the Synthesis of Eco-Friendly Polymeric Antioxidants
Current Organic Chemistry A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective
Current Gene Therapy TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design 3D-QSAR Studies on 4,5-Dihydro-1H-pyrazolo [4,3-h] Quinazolines as Plk-1, CDK2/A and Aur-A Serine/Threonine Kinase Inhibitors
Letters in Drug Design & Discovery Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Nucleophilic 18F-Fluorination of Complex Molecules in Activated Carbocyclic Aromatic Position
Current Radiopharmaceuticals Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Rat Resources in Biomedical Research
Current Pharmaceutical Biotechnology METCAM/MUC18 Expression and Cancer Metastasis
Current Genomics Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews Targeted Degradation of Proteins by Small Molecules: A Novel Tool for Functional Proteomics†
Combinatorial Chemistry & High Throughput Screening Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer
Reviews on Recent Clinical Trials Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism